文献速递乳腺癌

局部晚期乳腺癌患者中18F-氟脱氧葡萄糖正电子发射断层扫描-计算机断层扫描与传统分期对比的影响

Impact of 18F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Versus Conventional Staging in Patients With Locally Advanced Breast Cancer.
PubMed 文献 · J Clin Oncol · 2023-05-26

在局部晚期乳腺癌患者中,随机分配至18F-氟脱氧葡萄糖PET-CT组或传统分期组。PET-CT组将更多患者的分期上调至IV期(23% vs 11%),且接受联合模式治疗的患者比例更低(81% vs 89.2%)。

要点

  • PET-CT组43例(23%)分期上调至IV期,传统分期组21例(11%),绝对差异12.3%。
  • PET-CT组149例(81%)接受联合模式治疗,传统分期组165例(89.2%),绝对差异8.2%。
  • PET-CT组分期上调患者中35例(81.3%)治疗改变,传统分期组20例(95.2%)治疗改变。

核心结论

  • 在局部晚期乳腺癌患者中,PET-CT检测到比传统分期更多的远处转移,且接受联合模式治疗的PET-CT患者更少。
  • 该随机试验证明PET-CT分期策略的实用性。

研究设计与样本

  • 随机对照试验,纳入组织学证实的浸润性导管癌且TNM分期为III期或IIb期(T3N0,但不包括T2N1)的患者。
  • 来自加拿大安大略省六个区域癌症中心,同意参与的患者随机分配至18F-氟脱氧葡萄糖PET-CT组或传统分期组(骨扫描、胸部/腹部和盆腔CT)。
  • 主要终点为分期上调至IV期,关键次要结局为接受治愈性联合模式治疗。
  • 2016年12月至2022年4月期间,184例患者随机分配至全身PET-CT组,185例分配至传统分期组。

主要发现

  • PET-CT组43例(23%)分期上调至IV期,传统分期组21例(11%),绝对差异12.3%(95%CI 3.9至19.9),P=0.002。
  • PET-CT组43例分期上调患者中35例(81.3%)治疗改变,传统分期组21例中20例(95.2%)治疗改变。
  • PET-CT组149例(81%)接受联合模式治疗,传统分期组165例(89.2%),绝对差异8.2%(95%CI 0.1至15.4),P=0.03。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with locally advanced breast cancer (LABC) typically undergo staging tests at presentation. If staging does not detect metastases, treatment consists of curative intent combined modality therapy (neoadjuvant chemotherapy, surgery, and regional radiation). Positron emission tomography-computed tomography (PET-CT) may detect more asymptomatic distant metastases, but the evidence is based on uncontrolled studies. METHODS: For inclusion, patients had histological evidence of invasive ductal carcinoma of the breast and TNM stage III or IIb (T3N0, but not T2N1). Consenting patients from six regional cancer centers in Ontario were randomly assigned to 18F-labeled fluorodeoxyglucose PET-CT or conventional staging (bone scan, CT of the chest/abdomen and pelvis). The primary end point was upstaging to stage IV. A key secondary outcome was receiving curative intent combined modality therapy (ClinicalTrials.gov identifier: NCT02751710). RESULTS: Between December 2016 and April 2022, 184 patients were randomly assigned to whole-body PET-CT and 185 patients to conventional staging. Forty-three (23%) PET-CT patients were upstaged to stage IV compared with 21 (11%) conventional staged patients (absolute difference, 12.3% [95% CI, 3.9 to 19.9]; P = .002). Consequently, treatment was changed in 35 (81.3%) of 43 upstaged PET-CT patients and 20 (95.2%) of the 21 upstaged conventional patients. Subsequently, 149 (81%) patients in the PET-CT group received combined modality treatment versus 165 (89.2%) patients in the conventional staging group (absolute difference, 8.2% [95% CI, 0.1 to 15.4]; P = .03). CONCLUSION: In patients with LABC, PET-CT detected more distant metastases than conventional staging, and fewer PET-CT patients received combined modality therapy. Our randomized trial demonstrates the utility of the PET-CT staging strategy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Dayes IS, Metser U, Hodgson N, et al. Impact of 18F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Versus Conventional Staging in Patients With Locally Advanced Breast Cancer. J Clin Oncol. 2023. PMID: 37235845. doi:10.1200/JCO.23.00249

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。